Clinical trial
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
NCT03277729 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- December 5, 2017
- Completion date
- March 31, 2039
- Enrollment
- 53 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent b-cell non-hodgkin lymphoma, recurrent central nervous system lymphoma, recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent lymphoplasmacytic lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, recurrent transformed b-cell non-hodgkin lymphoma, recurrent transformed chronic lymphocytic leukemia, refractory b-cell non-hodgkin lymphoma, refractory central nervous system lymphoma, refractory chronic lymphocytic leukemia, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory lymphoplasmacytic lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory small lymphocytic lymphoma, refractory transformed b-cell non-hodgkin lymphoma, refractory transformed chronic lymphocytic leukemia, refractory transformed non-hodgkin lymphoma